Side-by-side · Research reference

MGFvsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED14/55 cited

BPhase 3HUMAN-REVIEWED8/39 cited

MGF

IGF-1Ec Splice Variant · Muscle-Specific

IGF-1EcSplice variantArmakolas 2016

24-AASynthetic E-domain

Animal onlyHuman evidence

SQ · Research context only

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

MGF

Thymosin α-1

Primary target

Satellite cells (Pax7+) in skeletal muscleMoore 2018

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

Mechanical stress → IGF-1Ec mRNA upregulation → Local E-domain peptide release → Satellite cell activation

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Satellite cell proliferation, myoblast differentiation, muscle fiber repair

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

—

Origin

Alternative splicing of IGF-1 gene (exons 4-6) produces IGF-1Ec precursor; E-domain cleaved post-translationallyArmakolas 2016 Vassilakos 2017

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

—

02Dosage Protocols

Parameter

MGF

Thymosin α-1

Synthetic peptide

24-amino-acid E-domain sequence

Corresponds to human IGF-1Ec exons 4-6 region.

—

Rodent cardiac model

200 μg/kg via peptide-eluting microstructures

Post-MI injection; improved ejection fraction by 8 weeks.

—

Acute delivery (mouse MI)

Single bolus within 12 hrs post-infarctionShioura 2014

Delayed decompensation; no human protocol established.

—

Human evidence

None — no published clinical trials

All dosing extrapolated from animal models.

—

Detection in doping

Full-length MGF detected via LC-MS in illicit productsThevis 2014

WADA-prohibited since 2005; no therapeutic indication.

—

Evidence basis

Animal models + in vitro only

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

Frequency

—

2× weekly (Mon/Thu typical)

Lower / starter dose

—

0.8 mg per injection

Duration

—

6–12 months for chronic indications

Reconstitution

—

Sterile water for injection per vial label

Timing

—

No specific time

Half-life

—

~2 hours plasma; tissue effect days

04Side Effects & Safety

Parameter

MGF

Thymosin α-1

Human safety data

None — no clinical trials published

—

Theoretical IGF-1 axis risk

Chronic IGF-1Ec overexpression linked to cancer progression (prostate, colorectal, breast)

—

Tumor promotion

IGF-1Ec overexpressed in osteosarcoma, colorectal polyps with dysplasia, endometrial cancer

—

Antibody development

Unknown — no longitudinal human exposure data

—

Local injection reaction

Presumed similar to other peptides (erythema, induration) — no direct evidence

—

Dysregulated expression with age

Older adults (70+ yrs) show blunted IGF-1Ec response post-exercise vs youngMoore 2018

—

Injection site reaction

—

Erythema, mild discomfort

GI symptoms

—

Rare nausea

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Cancer risk

—

No signal — used as adjuvant in oncology

Pregnancy / OB

—

Avoid

Absolute Contraindications

MGF

·Active malignancy or history of IGF-1-sensitive cancers (prostate, colorectal, breast, osteosarcoma)
·No established therapeutic use — investigational only

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

MGF

·Family history of IGF-1-axis malignancies
·Use outside research setting

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

MGF

Thymosin α-1

1. No validated protocol

MGF (E-domain peptide) has no approved clinical protocol. All published data derive from animal models or in vitro experiments.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Synthetic peptide form

Commercially available MGF corresponds to the 24-amino-acid human E-domain (hEc). Rodent E-domain (Eb) is structurally distinct and not interchangeable.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Animal delivery models

Rodent studies used peptide-eluting polymeric microstructures (cardiac) or direct intramuscular injection. Routes and doses non-translatable to humans.Peña 2015 Shioura 2014

2× weekly, e.g. Monday + Thursday.

4. WADA prohibition

MGF peptides prohibited in sport since 2005. Detection via LC-MS established for full-length MGF products.Thevis 2014

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Research context only

Any human use falls outside approved medical practice and regulatory frameworks. No safety or efficacy data exist.

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

MGF

+ BPC-157

Multi-pathway

View BPC-157 →

MGF activates satellite cells for muscle fiber repair; BPC-157 promotes angiogenesis, collagen synthesis, and tendon healing via distinct pathways (VEGF, FAK, integrin signaling). Theoretical synergy in post-injury contexts combines myogenic (MGF) and stromal (BPC-157) repair mechanisms. Both lack human validation.

MGF: No established dose
BPC-157: 250–500 mcg SQ near injury site
Context: Animal models only
Primary benefit: Theoretical multi-tissue repair (muscle + tendon/ligament)

+ TB-500

Moderate

View TB-500 →

TB-500 (thymosin beta-4 fragment) enhances actin polymerization, cell migration, and angiogenesis—complementary to MGF satellite cell activation. Both upregulated post-injury; combined use presumed additive for muscle regeneration in preclinical models.

MGF: No established dose
TB-500: 2–5 mg SQ weekly
Context: Animal models only
Primary benefit: Satellite cell activation + enhanced migration/angiogenesis

Thymosin α-1

— no documented stacks